MFH classification: Differentiating undifferentiated pleomorphic sarcoma in the 21st century

Expert Review of Anticancer Therapy

Volumn 9, Issue 8, 2009, Pages 1135-1144

  Matushansky, Igor ^b   Charytonowicz, Elizabeth ^b   Mills, Joslyn ^b   Siddiqi, Sara ^b   Hricik, Todd ^b   Cordon Cardo, Carlos ^a,b  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b Howard Hughes Medical Institute   (United States)

Author keywords

Classification; Differentiation; Malignant fibrous histiocytoma; Mesenchymal; Pleomorphic sarcomas; Stem cells; Therapy; Undifferentiated

Indexed keywords

5' NUCLEOTIDASE; BETA CATENIN; CD11B ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD79 ANTIGEN; CYCLIN D1; DICKKOPF 1 PROTEIN; ENDOGLIN; HLA DR ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P53; RETINOBLASTOMA PROTEIN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR NANOG; WNT PROTEIN;

CANCER CLASSIFICATION; CANCER RESEARCH; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CYTOGENETICS; GENE MUTATION; GENE OVEREXPRESSION; GIANT CELL TUMOR; HISTOGENESIS; HUMAN; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT TRANSFORMATION; MYXOSARCOMA; PROTEIN EXPRESSION; REVIEW; SOFT TISSUE SARCOMA;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; HISTIOCYTOMA, MALIGNANT FIBROUS; HISTORY, 21ST CENTURY; HUMANS; MESENCHYMAL STEM CELLS; SARCOMA;

EID: 70350648843     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.76     Document Type: Review

References (63)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Matushansky I, Maki RG. Mechanisms of sarcomagenesis. Hematol. Oncol. Clin. North Am. 19(3), 427-449 (2005).
3. Mertens F, Stromberg U, Mandahl N et al. Prognostically important chromosomal aberrations in soft tissue sarcomas: a report of the chromosomes and morphology (CHAMP) study group. Cancer Res. 62(14), 3980-3984 (2002). (Pubitemid 34791063)
4. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7(4), 233-245 (2007). (Pubitemid 46480968)
5. Shing DC, McMullan DJ, Roberts P et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res. 63(15), 4568-4576 (2003). (Pubitemid 36951031)
6. Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20(17), 3586-3591 (2002).
7. Brisset S, Schleiermacher G, Peter M et al. CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases. Cancer Genet. Cytogenet. 130(1), 57-61 (2001). (Pubitemid 32979167)
8. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat. Genet. 34(4), 369-376 (2003).
9. Jerusalem G, Rorive A, Ancion G, Hustinx R, Fillet G. Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations. Ann. Oncol. 17(Suppl. 10), 168-176 (2006). (Pubitemid 44542004)
10. Dennis JL, Hvidsten TR, Wit EC et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin. Cancer Res. 11(10), 3766-3772 (2005).
11. Sarcoma meta-analysis collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma meta-analysis collaboration. Lancet 350(9092), 1647-1654 (1997).
12. Sarcoma meta-analysis collaboration. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma meta-analysis collaboration (SMAC). Cochrane Database Syst. Rev. 2, CD001419 (2000).
13. Ozzello L, Stout AP, Murray MR. Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer 16, 331-344 (1963). •• Malignant fibrous histiocytoma (MFH) first identified as a distinct entity.
14. Enjoji M, Hashimoto H, Tsuneyoshi M, Iwasaki H. Malignant fibrous histiocytoma: a clinicopathologic study of 130 cases. Acta Pathol. Jpn 30(5), 727-741 (1980). (Pubitemid 11163551)
15. Kearney MM, Soule EH, Ivins JC. Malignant fibrous histiocytoma: a retrospective study of 167 cases. Cancer 45(1), 167-178 (1980).
16. Weiss SW. Malignant fibrous histiocytoma: a reaffirmation. Am. J. Surg. Pathol. 6(8), 773-784 (1982).
17. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 41(6), 2250-2266 (1978).
18. Enzinger FM. Malignant fibrous histiocytoma 20 years after Stout. Am. J. Surg. Pathol. 10(Suppl. 1), 43-53 (1986). • Good review of the reclassification of MFH that occurred in the 1980s and increasing concern about the growing classification of tumors as MFH.
19. Dehner LP. Malignant fibrous histiocytoma: nonspecific morphologic pattern, specific pathologic entity, or both? Arch. Pathol. Lab. Med. 112(3), 236-237 (1988).
20. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am. J. Surg. Pathol. 16(3), 213-228 (1992).
21. Daugaard S. Current soft-tissue sarcoma classifications. Eur. J. Cancer 40(4), 543-548 (2004).
22. Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 48(1), 3-12 (2006). •• Current classification of MFH as undifferentiated pleomorphic sarcoma.
23. Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology 48(1), 51-62 (2006).
24. Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the USA: an analysis of 12,114 cases. Cancer 113(3), 616-627 (2008).
25. Murphey MD. World Health Organization classification of bone and soft tissue tumors: modifications and implications for radiologists. Semin. Musculoskelet. Radiol. 11(3), 201-214 (2007).
26. Randall RL, Albritton KH, Ferney BJ, Layfield L. Malignant fibrous histiocytoma of soft tissue: an abandoned diagnosis. Am. J. Orthop. 33(12), 602-608 (2004).
27. Bahrami A, Ro JY, Ayala AG. An overview of testicular germ cell tumors. Arch. Pathol. Lab. Med. 131(8), 1267-1280 (2007). (Pubitemid 47257639)
28. Sesterhenn IA, Davis CJ Jr. Pathology of germ cell tumors of the testis. Cancer Control 11(6), 374-387 (2004).
29. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319(9), 525-532 (1988).
30. Pierce GB, Johnson LD. Differentiation and cancer. In Vitro 7(3), 140-145 (1971).
31. Orfao A, Schmitz G, Brando B et al. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin. Chem. 45(10), 1708-1717 (1999). (Pubitemid 29477326)
32. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. Stem cells 25(11), 2896-2902 (2007).
33. Castro-Malaspina H, Gay RE, Resnick G et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 56(2), 289-301 (1980). (Pubitemid 10043431)
34. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J. Cell. Mol. Med. 8(3), 301-316 (2004). (Pubitemid 44145494)
35. Gazziola C, Cordani N, Wasserman B et al. Malignant fibrous histiocytoma: a proposed cellular origin and identification of its characterizing gene transcripts. Int. J. Oncol. 23(2), 343-351 (2003). •• The first linkage of MFH to undifferentiated mesenchymal stem cells.
36. Smith JR, Pochampally R, Perry A, Hsu SC, Prockop DJ. Isolation of a highly clonogenic and multipotential subfraction of adult stem cells from bone marrow stroma. Stem Cells 22(5), 823-831 (2004). (Pubitemid 39166939)
37. Segal NH, Pavlidis P, Antonescu CR et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am. J. Pathol. 163(2), 691-700 (2003). (Pubitemid 36909430)
38. Matushansky I, Hernando E, Socci ND et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am. J. Pathol. 172(4), 1069-1080 (2008).
39. Matushansky I, Hernando E, Socci ND et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J. Clin. Invest. 117(11), 3248-3257 (2007). •• Demonstrated the concept of MFH as a transformed mesenchymal stem cell and the concept of epigenetic markers as indicative of undifferentiated state. (Pubitemid 350096982)
40. Eckfeldt CE, Mendenhall EM, Verfaillie CM. The molecular repertoire of the 'almighty' stem cell. Nat. Rev. Mol. Cell Biol. 6(9), 726-737 (2005).
41. Rao RR, Stice SL. Gene expression profiling of embryonic stem cells leads to greater understanding of pluripotency and early developmental events. Biol. Reprod. 71(6), 1772-1778 (2004).
42. Tasso R, Augello A, Carida M et al. Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds. Carcinogenesis 30(1), 150-157 (2009).
43. Yamate J, Ogata K, Yuasa T et al. Adipogenic, osteogenic and myofibrogenic differentiations of a rat malignant fibrous histiocytoma (MFH)-derived cell line, and a relationship of MFH cells with embryonal mesenchymal, perivascular and bone marrow stem cells. Eur. J. Cancer 43(18), 2747-2756 (2007). (Pubitemid 350151849)
44. Gregory CA, Singh H, Perry AS, Prockop DJ. The Wnt signaling inhibitor Dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J. Biol. Chem. 278(30), 28067-28078 (2003). (Pubitemid 36900004)
45. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/ beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell 8(5), 727-738 (2005). (Pubitemid 40585295)
46. Glass DA, Bialek P, Ahn JD et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8(5), 751-764 (2005). (Pubitemid 40585297)
47. Lee N, Smolarz AJ, Olson S et al. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br. J. Cancer 97(11), 1552-1559 (2007). (Pubitemid 350175854)
48. Longo KA, Wright WS, Kang S et al. Wnt10b inhibits development of white and brown adipose tissues. J. Biol. Chem. 279(34), 35503-35509 (2004). (Pubitemid 39100550)
49. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116(5), 1202-1209 (2006).
50. Ross SE, Hemati N, Longo KA et al. Inhibition of adipogenesis by Wnt signaling. Science 289(5481), 950-953 (2000).
51. Bernstein BE, Mikkelsen TS, Xie X et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2), 315-326 (2006).
52. Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist 7(4), 348-359 (2002).
53. Matushansky I, Maki R, Cordon-Cardo C. A context dependent role for Wnt signaling in tumorigenesis and stem cells. Cell Cycle 7(6), 720-724 (2008).
54. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells: perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66(19), 9339-9344 (2006).
55. Fujii H, Honoki K, Tsujiuchi T et al. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int. J. Oncol. 34(5), 1381-1386 (2009).
56. Gibbs CP, Kukekov VG, Reith JD et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7(11), 967-976 (2005).
57. Jones RJ, Armstrong SA. Cancer stem cells in hematopoietic malignancies. Biol. Blood Marrow Transplant 14(Suppl. 1), 12-16 (2008).
58. Gumucio DL, Fagoonee S, Qiao XT et al. Tissue stem cells and cancer stem cells: potential implications for gastric cancer. Panminerva Med. 50(1), 65-71 (2008).
59. Zhao R, Daley GQ. From fibroblasts to iPS cells: induced pluripotency by defined factors. J. Cell. Biochem. 105(4), 949-955 (2008).
60. Hochedlinger K, Plath K. Epigenetic reprogramming and induced pluripotency. Development 136(4), 509-523 (2009).
61. Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell 2(3), 175-178 (2002).
62. Subramanian S, Lui WO, Lee CH et al. MicroRNA expression signature of human sarcomas. Oncogene 27(14), 2015-2026 (2008).
63. Cordon-Cardo C, Kotsianti A, Verbel DA et al. Improved prediction of prostate cancer recurrence through systems pathology. J. Clin. Invest. 117(7), 1876-1883 (2007).